A conserved dendritic-cell regulatory program limits antitumour immunity

Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control the response to checkpoint blockade in preclinical models and are associated with better overall survival in patients w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nature
Autors principals: Maier, Barbara, Leader, Andrew M., Chen, Steven T., Tung, Navpreet, Chang, Christie, LeBerichel, Jessica, Chudnovskiy, Aleksey, Maskey, Shrisha, Walker, Laura, Finnigan, John P., Kirkling, Margaret E., Reizis, Boris, Ghosh, Sourav, D’Amore, Natalie Roy, Bhardwaj, Nina, Rothlin, Carla V., Wolf, Andrea, Flores, Raja, Marron, Thomas, Rahman, Adeeb H., Kenigsberg, Ephraim, Brown, Brian D., Merad, Miriam
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787191/
https://ncbi.nlm.nih.gov/pubmed/32269339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-020-2134-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars